Blade Air Mobility Announces Fourth Quarter 2024 Results
Blade Air Mobility (NASDAQ: BLDE) reported strong Q4 2024 financial results, with revenue increasing 14.5% to $54.4 million. Excluding Canada operations, which were discontinued in August 2024, revenue grew 22.1% year-over-year.
The company achieved its first full-year of Adjusted EBITDA profitability, with a $17.8 million improvement to $1.2 million in FY 2024. Net loss improved by $28.8 million to $(27.3) million. The Medical segment showed impressive growth with Adjusted EBITDA improving 119.6% to $5.5 million in Q4, while the Passenger segment achieved $3.6 million in Adjusted EBITDA for full-year 2024.
Key Q4 metrics include:
- Flight Profit increased 39.7% to $12.6 million
- Medical revenue grew 13.7% to $36.4 million
- Short Distance revenue (excluding Canada) increased 17.7%
- Jet and Other revenue surged 84.7% to $8.8 million
The company ended FY 2024 with $127.1 million in cash and short-term investments, and reaffirmed guidance for double-digit millions in Adjusted EBITDA for 2025.
Blade Air Mobility (NASDAQ: BLDE) ha riportato risultati finanziari solidi per il quarto trimestre del 2024, con un aumento del fatturato del 14,5% a $54,4 milioni. Escludendo le operazioni in Canada, che sono state interrotte nell'agosto 2024, il fatturato è cresciuto del 22,1% rispetto all'anno precedente.
L'azienda ha raggiunto il suo primo anno completo di redditività dell'EBITDA rettificato, con un miglioramento di $17,8 milioni a $1,2 milioni nell'anno fiscale 2024. La perdita netta è migliorata di $28,8 milioni a $(27,3) milioni. Il segmento medico ha mostrato una crescita impressionante, con un EBITDA rettificato che è migliorato del 119,6% a $5,5 milioni nel quarto trimestre, mentre il segmento passeggeri ha raggiunto $3,6 milioni di EBITDA rettificato per l'intero anno 2024.
I principali indicatori del quarto trimestre includono:
- Il profitto dei voli è aumentato del 39,7% a $12,6 milioni
- Il fatturato medico è cresciuto del 13,7% a $36,4 milioni
- Il fatturato per brevi distanze (escludendo il Canada) è aumentato del 17,7%
- Il fatturato da jet e altri è aumentato dell'84,7% a $8,8 milioni
L'azienda ha chiuso l'anno fiscale 2024 con $127,1 milioni in contante e investimenti a breve termine, e ha confermato le previsioni per decine di milioni di EBITDA rettificato per il 2025.
Blade Air Mobility (NASDAQ: BLDE) reportó resultados financieros sólidos para el cuarto trimestre de 2024, con un aumento del 14.5% en los ingresos, alcanzando los $54.4 millones. Excluyendo las operaciones en Canadá, que se interrumpieron en agosto de 2024, los ingresos crecieron un 22.1% interanual.
La compañía logró su primer año completo de rentabilidad en EBITDA ajustado, con una mejora de $17.8 millones a $1.2 millones en el año fiscal 2024. La pérdida neta mejoró en $28.8 millones, alcanzando $(27.3) millones. El segmento médico mostró un crecimiento impresionante, con un EBITDA ajustado que mejoró un 119.6% a $5.5 millones en el cuarto trimestre, mientras que el segmento de pasajeros alcanzó $3.6 millones en EBITDA ajustado para todo el año 2024.
Los principales indicadores del cuarto trimestre incluyen:
- El beneficio de vuelos aumentó un 39.7% a $12.6 millones
- Los ingresos médicos crecieron un 13.7% a $36.4 millones
- Los ingresos por distancias cortas (excluyendo Canadá) aumentaron un 17.7%
- Los ingresos por jets y otros aumentaron un 84.7% a $8.8 millones
La compañía cerró el año fiscal 2024 con $127.1 millones en efectivo e inversiones a corto plazo, y reafirmó sus proyecciones de decenas de millones en EBITDA ajustado para 2025.
Blade Air Mobility (NASDAQ: BLDE)는 2024년 4분기 재무 결과가 강력하다고 보고했으며, 수익이 14.5% 증가하여 5440만 달러에 달했습니다. 2024년 8월에 중단된 캐나다 운영을 제외하면, 수익은 전년 대비 22.1% 증가했습니다.
회사는 조정된 EBITDA 수익성이 처음으로 연간 달성되었으며, 2024 회계연도에 1780만 달러 개선되어 120만 달러에 도달했습니다. 순손실은 2880만 달러 개선되어 $(2730)만 달러가 되었습니다. 의료 부문은 4분기 조정된 EBITDA가 119.6% 개선되어 550만 달러에 달하는 인상적인 성장을 보여주었으며, 승객 부문은 2024년 전체 연도 동안 360만 달러의 조정된 EBITDA를 달성했습니다.
4분기 주요 지표는 다음과 같습니다:
- 비행 수익이 39.7% 증가하여 1260만 달러에 달했습니다
- 의료 수익이 13.7% 증가하여 3640만 달러에 달했습니다
- 단거리 수익(캐나다 제외)이 17.7% 증가했습니다
- 제트 및 기타 수익이 84.7% 증가하여 880만 달러에 달했습니다
회사는 2024 회계연도를 1억 2710만 달러의 현금 및 단기 투자로 마감했으며, 2025년을 위한 조정된 EBITDA에서 두 자릿수 수백만 달러의 가이던스를 재확인했습니다.
Blade Air Mobility (NASDAQ: BLDE) a annoncé des résultats financiers solides pour le quatrième trimestre 2024, avec une augmentation des revenus de 14,5 % à 54,4 millions de dollars. En excluant les opérations au Canada, qui ont été arrêtées en août 2024, les revenus ont augmenté de 22,1 % d'une année sur l'autre.
L'entreprise a atteint sa première année complète de rentabilité de l'EBITDA ajusté, avec une amélioration de 17,8 millions de dollars à 1,2 million de dollars pour l'exercice 2024. La perte nette s'est améliorée de 28,8 millions de dollars pour atteindre $(27,3) millions. Le secteur médical a montré une croissance impressionnante avec un EBITDA ajusté amélioré de 119,6 % à 5,5 millions de dollars au quatrième trimestre, tandis que le secteur passager a atteint 3,6 millions de dollars d'EBITDA ajusté pour l'année complète 2024.
Les indicateurs clés du quatrième trimestre incluent:
- Le bénéfice des vols a augmenté de 39,7 % pour atteindre 12,6 millions de dollars
- Les revenus médicaux ont augmenté de 13,7 % pour atteindre 36,4 millions de dollars
- Les revenus des courtes distances (hors Canada) ont augmenté de 17,7 %
- Les revenus des jets et autres ont explosé de 84,7 % pour atteindre 8,8 millions de dollars
L'entreprise a terminé l'exercice 2024 avec 127,1 millions de dollars en liquidités et investissements à court terme, et a réaffirmé ses prévisions de dizaines de millions d'EBITDA ajusté pour 2025.
Blade Air Mobility (NASDAQ: BLDE) hat starke Finanzzahlen für das vierte Quartal 2024 berichtet, mit einem Umsatzanstieg von 14,5% auf 54,4 Millionen Dollar. Ohne die Kanada-Operationen, die im August 2024 eingestellt wurden, wuchs der Umsatz im Jahresvergleich um 22,1%.
Das Unternehmen erreichte im Geschäftsjahr 2024 sein erstes volles Jahr mit positiver Adjusted EBITDA, mit einer Verbesserung um 17,8 Millionen Dollar auf 1,2 Millionen Dollar. Der Nettoverlust verbesserte sich um 28,8 Millionen Dollar auf $(27,3) Millionen. Der medizinische Sektor zeigte ein beeindruckendes Wachstum, wobei das Adjusted EBITDA im vierten Quartal um 119,6% auf 5,5 Millionen Dollar anstieg, während der Passagiersektor für das gesamte Jahr 2024 ein Adjusted EBITDA von 3,6 Millionen Dollar erzielte.
Wichtige Kennzahlen für das vierte Quartal umfassen:
- Der Fluggewinn stieg um 39,7% auf 12,6 Millionen Dollar
- Der medizinische Umsatz wuchs um 13,7% auf 36,4 Millionen Dollar
- Der Umsatz aus Kurzstrecken (ohne Kanada) stieg um 17,7%
- Der Umsatz aus Jets und anderen stieg um 84,7% auf 8,8 Millionen Dollar
Das Unternehmen schloss das Geschäftsjahr 2024 mit 127,1 Millionen Dollar in bar und kurzfristigen Investitionen ab und bestätigte die Prognose für zweistellige Millionenbeträge im Adjusted EBITDA für 2025.
- First full-year of Adjusted EBITDA profitability achieved at $1.2 million
- Medical segment Adjusted EBITDA grew 119.6% to $5.5 million in Q4
- Revenue excluding Canada increased 22.1% in Q4
- Flight Profit increased 39.7% to $12.6 million in Q4
- Net loss improved by $28.8 million year-over-year
- Still operating at a net loss of $(27.3) million in FY 2024
- Q4 2024 Adjusted EBITDA remained negative at $(0.4) million
- Operating Cash Flow negative at $(1.8) million in Q4
- Short Distance revenue decreased 14.7% to $9.1 million in Q4
Insights
Blade Air Mobility's Q4 2024 results demonstrate strong financial trajectory improvement, highlighted by their first full year of Adjusted EBITDA profitability at
The company significantly reduced its net loss to
Particularly noteworthy is the segment performance: Medical Segment Adjusted EBITDA surged
With
- Full-year net loss improved by
$28.8 million versus the prior year to$(27.3) million in FY 2024; Adjusted EBITDA improved by$17.8 million versus the prior year to$1.2 million in FY 2024(1) - Full-year Passenger Segment Adjusted EBITDA of
$3.6 million in 2024 represents an$8.6 million increase versus the prior year - Q4 revenue increased
14.5% versus the prior year to$54.4 million in 2024. Excluding Canada, which we exited in August 2024, revenue increased22.1% versus the prior year period(1) - Net loss improved by
$24.1 million versus the prior year to$(9.8) million in Q4 2024; Adjusted EBITDA improved by$4.9 million versus the prior year to$(0.4) million in Q4 2024(1) - Medical Segment Adjusted EBITDA improved
119.6% to$5.5 million in Q4 2024 versus the prior year - Reaffirming guidance for double-digit millions of Adjusted EBITDA in 2025(2)
NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Blade Air Mobility, Inc. (Nasdaq: BLDE, "Blade" or the "Company"), today announced financial results for the fourth quarter ended December 31, 2024.
| GAAP FINANCIAL RESULTS (in thousands except percentages, unaudited) | |||||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||
| 2024 | 2023 | % Change | 2024 | 2023 | % Change | ||||||||||||||||
| Revenue | $ | 54,357 | $ | 47,478 | 14.5 | % | $ | 248,693 | $ | 225,180 | 10.4 | % | |||||||||
| Cost of revenue | $ | 41,768 | $ | 38,468 | 8.6 | % | $ | 189,774 | $ | 183,058 | 3.7 | % | |||||||||
| Software development | 743 | 988 | (24.8 | )% | 3,184 | 4,627 | (31.2 | )% | |||||||||||||
| General and administrative | 18,954 | 41,242 | (54.0 | )% | 81,711 | 95,174 | (14.1 | )% | |||||||||||||
| Selling and marketing | 1,264 | 2,413 | (47.6 | )% | 7,950 | 10,438 | (23.8 | )% | |||||||||||||
| Total operating expenses | $ | 62,729 | $ | 83,111 | (24.5 | )% | $ | 282,619 | $ | 293,297 | (3.6 | )% | |||||||||
| Loss from operations | $ | (8,372 | ) | $ | (35,633 | ) | (76.5 | )% | $ | (33,926 | ) | $ | (68,117 | ) | (50.2 | )% | |||||
| Net loss | $ | (9,793 | ) | $ | (33,941 | ) | (71.1 | )% | $ | (27,307 | ) | $ | (56,076 | ) | (51.3 | )% | |||||
| Gross profit | $ | 9,026 | $ | 4,105 | 119.9 | % | $ | 40,652 | $ | 22,458 | 81.0 | % | |||||||||
| Gross margin | 16.6 | % | 8.6 | % | 800bps | 16.3 | % | 10.0 | % | 630bps | |||||||||||
(1) See "Use of Non-GAAP Financial Measures" and "Key Metrics and Non-GAAP Financial Information" sections attached to this release for an explanation of Non-GAAP measures used and reconciliations to the most directly comparable GAAP financial measure.
(2) We have not reconciled the forward-looking Adjusted EBITDA guidance included above to the most directly comparable GAAP measure because this cannot be done without unreasonable effort due to the variability and low visibility with respect to certain costs, the most significant of which are incentive compensation (including stock-based compensation), transaction-related expenses, certain fair value measurements, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.
| NON-GAAP(1) FINANCIAL RESULTS (in thousands except percentages, unaudited) | |||||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||
| 2024 | 2023 | Change | 2024 | 2023 | % Change | ||||||||||||||||
| Revenue | $ | 54,357 | $ | 47,478 | 14.5 | % | $ | 248,693 | $ | 225,180 | 10.4 | % | |||||||||
| Cost of revenue | 41,768 | 38,468 | 8.6 | % | 189,774 | 183,058 | 3.7 | % | |||||||||||||
| Flight Profit | 12,589 | 9,010 | 39.7 | % | 58,919 | 42,122 | 39.9 | % | |||||||||||||
| Flight Margin | 23.2 | % | 19.0 | % | 418bps | 23.7 | % | 18.7 | % | 499bps | |||||||||||
| Adjusted SG&A | 13,618 | 14,338 | (5.0 | )% | 59,388 | 58,989 | 0.7 | % | |||||||||||||
| Depreciation included in cost of revenue | 642 | 80 | NM(2) | 1,674 | 234 | NM(2) | |||||||||||||||
| Adjusted EBITDA | $ | (387 | ) | $ | (5,248 | ) | (92.6 | )% | $ | 1,205 | $ | (16,633 | ) | NM(2) | |||||||
| Adjusted EBITDA as a percentage of Revenue | (0.7 | )% | (11.1 | )% | 1,034bps | 0.5 | % | (7.4 | )% | NM(2) | |||||||||||
| Passenger Adjusted EBITDA | $ | (156 | ) | $ | (2,635 | ) | (94.1 | )% | $ | 3,568 | $ | (4,988 | ) | NM(2) | |||||||
| Medical Adjusted EBITDA | $ | 5,502 | $ | 2,505 | 119.6 | % | $ | 19,286 | $ | 10,754 | 79.3 | % | |||||||||
| Adjusted unallocated corporate expenses and software development | $ | (5,733 | ) | $ | (5,118 | ) | 12.0 | % | $ | (21,649 | ) | $ | (22,399 | ) | (3.3 | )% | |||||
(1) See "Use of Non-GAAP Financial Measures" and "Key Metrics and Non-GAAP Financial Information" sections attached to this release for an explanation of Non-GAAP measures used and reconciliations to the most directly comparable GAAP financial measure.
(2) Not meaningful.
"As promised, we are pleased to deliver our first full-year of Adjusted EBITDA profitability as significant revenue growth and margin expansion in both Medical and Passenger drove a
Wiesenthal added, "While we continue to drive further cost efficiencies in our Passenger business, we remain laser focused on maximizing growth in Urban Air Mobility products such as our New York City airport transfer service, which saw high-teens year-over-year revenue expansion in Q4. Services like Blade Airport are key to accelerating and de-risking our planned shift from helicopters to eVTOL. This combination of revenue growth and cost efficiencies enabled us to improve on our achievement of positive trailing twelve month Passenger Segment Adjusted EBITDA last quarter, more than a year ahead of our target, by posting
"We have successfully positioned both the Medical and Passenger businesses to benefit from improved economies of scale, driven by our aircraft investments and additional capacity purchase agreements that enable us to use our increasing volumes to drive margin expansion," said Will Heyburn, Chief Financial Officer. "Our
Heyburn added, "We're also pleased to report that Q4 2024 was our first quarter with Medical Segment Adjusted EBITDA margins above our
"Early results following our European restructuring have been very encouraging with strong year-over-year revenue growth and solid profitability improvement in the winter ski season to-date," said Melissa Tomkiel, President. "In Medical, our aircraft investments continue to provide much more than just financial benefits, illustrated by our expected launch with two new transplant centers in April, following competitive processes that required direct aircraft ownership."
Fourth Quarter Ended December 31, 2024 Financial Highlights
- Total revenue increased
14.5% to$54.4 million in the current quarter versus$47.5 million in the prior year period, driven primarily by growth in both our Passenger and Medical segments. Excluding Canada, which we exited in August 2024, revenue increased22.1% , versus the prior year period. - Flight Profit(1) increased
39.7% to$12.6 million in the current quarter versus$9.0 million in the prior year period, driven by strong growth in both the Medical and Passenger segments. - Flight Margin(1) improved to
23.2% in the current quarter from19.0% in the prior year period. Passenger Flight Margin expansion was driven by margin improvements in Short Distance and Jet & Other Passenger, along with our exit from Canada. In Medical, Flight Margin expansion was primarily driven by our aircraft capacity strategy. - Medical revenue increased
13.7% to$36.4 million in the current quarter versus$32.0 million in the prior year period. The increase in Air revenue was primarily driven by trip volume partially offset by a reduction in block hours per trip as we increased the size of our dedicated fleet and positioned aircraft closer to our customers, reducing repositioning cost while improving our ability to react quickly. Ground and TOPS, our organ matching service, grew faster than the Medical segment average. - Short Distance revenue decreased
14.7% to$9.1 million in the current quarter versus$10.7 million in the prior year period. Excluding Canada, which we exited in August 2024, Short Distance revenue increased17.7% (1) versus the prior year period. The increase was primarily driven by Leisure, Other Short Distance and New York Airport. - Jet and Other revenue increased
84.7% to$8.8 million in the current quarter versus$4.8 million in the prior year period primarily driven by higher flight volumes. - Net loss improved by
$24.1 million versus the prior year to$(9.8) million in the current quarter driven primarily by a$27.3 million improvement in loss from operations partially offset by other non-operating income and income taxes. - Adjusted EBITDA(1) increased by
$4.9 million year-over-year to$(0.4) million in the current quarter versus$(5.2) million in the prior year period primarily due to a$3.0 million improvement in Medical Segment Adjusted EBITDA and a$2.5 million increase in Passenger Segment Adjusted EBITDA in the quarter partially offset by an increase in Adjusted Unallocated Corporate Expenses and Software Development. - Operating Cash Flow increased by
$7.6 million to$(1.8) million in the current quarter. Capital expenditures of$5.0 million were driven primarily by the$3.2 million purchase of aircraft in the Medical segment. Free Cash Flow, Before Aircraft Acquisitions, which is net of all capital expenditures, including aircraft maintenance expenses, but excludes the impact of aircraft acquisitions, increased by$5.8 million to$(3.6) million in the current quarter. - Ended FY 2024 with
$127.1 million in cash and short term investments.
(1) See "Use of Non-GAAP Financial Measures" and "Key Metrics and Non-GAAP Financial Information" sections attached to this release for an explanation of Non-GAAP measures used and reconciliations to the most directly comparable GAAP financial measure.
Business Highlights and Recent Updates
- In Medical, we owned nine aircraft at the end of December 2024 and our tenth aircraft entered service in February 2025. We continue to expect that our owned fleet will represent approximately one third of our Medical flight hours in 2025, with the majority of flight hours remaining on third-party aircraft.
- Our organ placement service offering ("TOPS") ended the year with six contracted customers and a strong sales pipeline.
- We announced an alliance with Skyports Infrastructure to launch a pilot program that will expand Blade’s existing by-the-seat helicopter transfer service, connecting the Downtown Manhattan Heliport and John F. Kennedy International Airport (“JFK”), starting in April of this year.
- In March, Blade introduced a new mobile app that offers an enhanced user experience, easy flight booking, flexible payment options, trip management functionality and many more features.
Financial Outlook(2)
For the full year 2025, we expect:
- Revenue of
$245 -265 million - Double-digit Adjusted EBITDA
Conference Call
The Company will conduct a conference call starting at 8:00 a.m. ET on Thursday March 13, 2025 to discuss the results for the fourth quarter ended December 31, 2024.
A live audio-only webcast of the call may be accessed from the Investor Relations section of the Company’s website at https://ir.blade.com/. An archived replay of the call will be available on the Investor Relations section of the Company's website for one year.
(1) See "Use of Non-GAAP Financial Measures" and "Key Metrics and Non-GAAP Financial Information" sections attached to this release for an explanation of Non-GAAP measures used and reconciliations to the most directly comparable GAAP financial measure.
(2) We have not reconciled the forward-looking Adjusted EBITDA guidance included above to the most directly comparable GAAP measure because this cannot be done without unreasonable effort due to the variability and low visibility with respect to certain costs, the most significant of which are incentive compensation (including stock-based compensation), transaction-related expenses, certain fair value measurements, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.
Use of Non-GAAP Financial Information
Blade believes that the non-GAAP measures discussed below, viewed in addition to and not in lieu of our reported U.S. Generally Accepted Accounting Principles ("GAAP") results, provide useful information to investors by providing a more focused measure of operating results, enhance the overall understanding of past financial performance and future prospects, and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making. The non-GAAP measures presented herein may not be comparable to similarly titled measures presented by other companies. Adjusted EBITDA, Adjusted Unallocated Corporate Expenses, SG&A, Adjusted SG&A, Flight Profit, Flight Margin, Free Cash Flow and Free Cash Flow, before Aircraft Acquisitions and revenue excluding the impact of Canada have been reconciled to the nearest GAAP measure in the tables within this press release.
Adjusted EBITDA – Blade reports Adjusted EBITDA, which is a non-GAAP financial measure. Blade defines Adjusted EBITDA as net loss adjusted to exclude depreciation and amortization, stock-based compensation, change in fair value of warrant liabilities, interest income and expense, income tax, realized gains and losses on short-term investments, impairment of intangible assets and certain other non-recurring items that management does not believe are indicative of ongoing Company operating performance and would impact the comparability of results between periods.
Adjusted Unallocated Corporate Expenses – Blade defines Adjusted Unallocated Corporate Expenses as expenses that cannot be allocated to either of our reporting segments (Passenger and Medical) and therefore attributable to our Corporate expenses and software development, less non-cash items and certain other non-recurring items that management does not believe are indicative of ongoing Company operating performance and would impact the comparability of results between periods.
SG&A and Adjusted SG&A – Blade defines SG&A as total operating expenses excluding cost of revenue. Blade defines Adjusted SG&A as total operating expenses excluding cost of revenue and excluding non-cash items and certain other non-recurring items that management does not believe are indicative of ongoing Company operating performance and would impact the comparability of results between periods.
Flight Profit and Flight Margin – Blade defines Flight Profit as revenue less cost of revenue. Cost of revenue consists of flight costs paid to operators of aircraft and vehicles, landing fees, depreciation of aircraft and vehicles, operating lease cost, internal costs incurred in generating organ ground transportation revenue using the Company's owned vehicles and costs of operating our owned aircraft including fuel, management fees paid to the operator, maintenance costs and pilot salaries. Blade defines Flight Margin for a period as Flight Profit for the period divided by revenue for the same period. Blade believes that Flight Profit and Flight Margin provide an important measure of the profitability of the Company's flight and ground operations, as they focus solely on the non-discretionary direct costs associated with those operations such as third-party variable costs and costs of owning and operating Blade's owned aircraft.
Free Cash Flow and Free Cash Flow, before Aircraft Acquisitions – Blade defines Free Cash Flow as net cash provided by / (used in) operating activities less capital expenditures and capitalized software development costs. Blade also reports Free Cash Flow, before Aircraft Acquisitions, which is Free Cash Flow excluding cash outflows for aircraft acquisitions. Blade believes that Free Cash Flow and Free Cash Flow, before Aircraft Acquisitions provide important insights into the cash-generating capability of the business, with Free Cash Flow, before Aircraft Acquisition specifically highlighting the cash generated by our core operations before the impact of discretionary strategic investments in new aircraft.
We have also shown revenue and Short Distance revenue excluding the impact of Canada in this release. These amounts reflect total revenue and short distance revenue, respectively, excluding the activity in Canada in both the current and the prior year periods. The Company discontinued its operations in Canada on August 31, 2024. Management believes that presenting this information enhances the comparability of results between periods.
Financial Results
| BLADE AIR MOBILITY, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share data, unaudited) | |||||||
| December 31, 2024 | December 31, 2023 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 18,378 | $ | 27,873 | |||
| Restricted cash | 1,269 | 1,148 | |||||
| Accounts receivable, net of allowance of | 21,591 | 21,005 | |||||
| Short-term investments | 108,757 | 138,264 | |||||
| Prepaid expenses and other current assets | 10,747 | 17,971 | |||||
| Total current assets | 160,742 | 206,261 | |||||
| Non-current assets: | |||||||
| Property and equipment, net | 30,918 | 2,899 | |||||
| Intangible assets, net | 13,653 | 20,519 | |||||
| Goodwill | 41,050 | 40,373 | |||||
| Operating right-of-use asset | 8,876 | 23,484 | |||||
| Other non-current assets | 1,436 | 1,402 | |||||
| Total assets | $ | 256,675 | $ | 294,938 | |||
| Liabilities and Stockholders' Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable and accrued expenses | $ | 12,766 | $ | 23,859 | |||
| Deferred revenue | 6,656 | 6,845 | |||||
| Operating lease liability, current | 3,304 | 4,787 | |||||
| Total current liabilities | 22,726 | 35,491 | |||||
| Non-current liabilities: | |||||||
| Warrant liability | 5,808 | 4,958 | |||||
| Operating lease liability, long-term | 6,018 | 19,738 | |||||
| Deferred tax liability | 185 | 451 | |||||
| Total liabilities | 34,737 | 60,638 | |||||
| Stockholders' Equity | |||||||
| Preferred stock, | — | — | |||||
| Common stock, | 7 | 7 | |||||
| Additional paid in capital | 407,076 | 390,083 | |||||
| Accumulated other comprehensive income | 1,753 | 3,964 | |||||
| Accumulated deficit | (186,898 | ) | (159,754 | ) | |||
| Total stockholders' equity | 221,938 | 234,300 | |||||
| Total Liabilities and Stockholders' Equity | $ | 256,675 | $ | 294,938 | |||
| BLADE AIR MOBILITY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data, unaudited) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenue | $ | 54,357 | $ | 47,478 | $ | 248,693 | $ | 225,180 | |||||||
| Operating expenses | |||||||||||||||
| Cost of revenue | 41,768 | 38,468 | 189,774 | 183,058 | |||||||||||
| Software development | 743 | 988 | 3,184 | 4,627 | |||||||||||
| General and administrative | 18,954 | 41,242 | 81,711 | 95,174 | |||||||||||
| Selling and marketing | 1,264 | 2,413 | 7,950 | 10,438 | |||||||||||
| Total operating expenses | 62,729 | 83,111 | 282,619 | 293,297 | |||||||||||
| Loss from operations | (8,372 | ) | (35,633 | ) | (33,926 | ) | (68,117 | ) | |||||||
| Other non-operating income (expense) | |||||||||||||||
| Interest income | 1,590 | 2,264 | 7,214 | 8,442 | |||||||||||
| Change in fair value of warrant liabilities | (3,116 | ) | (1,698 | ) | (850 | ) | 2,125 | ||||||||
| Realized gain from sales of short-term investments | — | 103 | — | 8 | |||||||||||
| Total other non-operating (expense) income | (1,526 | ) | 669 | 6,364 | 10,575 | ||||||||||
| Loss before income taxes | (9,898 | ) | (34,964 | ) | (27,562 | ) | (57,542 | ) | |||||||
| Income tax benefit | (105 | ) | (1,023 | ) | (255 | ) | (1,466 | ) | |||||||
| Net loss | $ | (9,793 | ) | $ | (33,941 | ) | $ | (27,307 | ) | $ | (56,076 | ) | |||
| BLADE AIR MOBILITY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands, unaudited) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Cash Flows From Operating Activities: | |||||||||||||||
| Net loss | $ | (9,793 | ) | $ | (33,941 | ) | $ | (27,307 | ) | $ | (56,076 | ) | |||
| Adjustments to reconcile net loss to net cash and restricted cash used in | |||||||||||||||
| Depreciation and amortization | 1,530 | 1,806 | 5,962 | 7,111 | |||||||||||
| Stock-based compensation | 4,526 | 3,153 | 19,893 | 12,501 | |||||||||||
| Change in fair value of warrant liabilities | 3,116 | 1,698 | 850 | (2,125 | ) | ||||||||||
| Excess of lease liability over operating right-of-use assets | — | — | (123 | ) | — | ||||||||||
| Gain on lease modification | (547 | ) | — | (622 | ) | — | |||||||||
| Accretion of interest income on held-to-maturity securities | (870 | ) | (1,803 | ) | (3,990 | ) | (6,519 | ) | |||||||
| Deferred tax benefit | (105 | ) | (1,023 | ) | (255 | ) | (1,466 | ) | |||||||
| Impairment of intangible assets | — | 20,753 | 5,759 | 20,753 | |||||||||||
| Bad debt expense | 167 | (8 | ) | 335 | 163 | ||||||||||
| Other (1) | (6 | ) | (55 | ) | (12 | ) | 46 | ||||||||
| Changes in operating assets and liabilities: | |||||||||||||||
| Prepaid expenses and other current assets | (1,960 | ) | (4,928 | ) | 6,352 | (6,032 | ) | ||||||||
| Accounts receivable | 2,613 | 125 | (998 | ) | (10,254 | ) | |||||||||
| Other non-current assets | (562 | ) | 12 | (70 | ) | 4 | |||||||||
| Operating right-of-use assets/lease liabilities | 83 | (42 | ) | 164 | 379 | ||||||||||
| Accounts payable and accrued expenses | (2 | ) | 4,963 | (8,338 | ) | 9,049 | |||||||||
| Deferred revenue | 58 | (30 | ) | (119 | ) | 117 | |||||||||
| Net cash used in operating activities | (1,752 | ) | (9,320 | ) | (2,519 | ) | (32,349 | ) | |||||||
| Cash Flows From Investing Activities: | |||||||||||||||
| Acquisitions, net of cash acquired | — | — | (2,230 | ) | — | ||||||||||
| Capitalized software development costs | (459 | ) | — | (2,119 | ) | — | |||||||||
| Investment in joint venture | — | (39 | ) | — | (39 | ) | |||||||||
| Purchase of property and equipment | (4,583 | ) | (24 | ) | (30,875 | ) | (2,109 | ) | |||||||
| Proceeds from disposal of property and equipment | 7 | 138 | 13 | 138 | |||||||||||
| Purchase of short-term investments | — | — | — | (135 | ) | ||||||||||
| Proceeds from sales of short-term investments | — | — | — | 20,532 | |||||||||||
| Purchase of held-to-maturity investments | (489 | ) | — | (143,255 | ) | (265,835 | ) | ||||||||
| Proceeds from maturities of held-to-maturity investments | 9,500 | — | 177,450 | 264,537 | |||||||||||
| Net cash provided by / (used in) investing activities | 3,976 | 75 | (1,016 | ) | 17,089 | ||||||||||
| Cash Flows From Financing Activities: | |||||||||||||||
| Proceeds from the exercise of common stock options | 44 | 7 | 168 | 70 | |||||||||||
| Taxes paid related to net share settlement of equity awards | (3,918 | ) | (30 | ) | (5,683 | ) | (146 | ) | |||||||
| Repurchase and retirement of common stock | — | — | (244 | ) | — | ||||||||||
| Net cash used in financing activities | (3,874 | ) | (23 | ) | (5,759 | ) | (76 | ) | |||||||
| Effect of foreign exchange rate changes on cash balances | (109 | ) | 15 | (80 | ) | (66 | ) | ||||||||
| Net decrease in cash and cash equivalents and restricted cash | (1,759 | ) | (9,253 | ) | (9,374 | ) | (15,402 | ) | |||||||
| Cash and cash equivalents and restricted cash - beginning | 21,406 | 38,274 | 29,021 | 44,423 | |||||||||||
| Cash and cash equivalents and restricted cash - ending | $ | 19,647 | $ | 29,021 | $ | 19,647 | $ | 29,021 | |||||||
| Reconciliation to consolidated balance sheets | |||||||||||||||
| Cash and cash equivalents | $ | 18,378 | $ | 27,873 | $ | 18,378 | $ | 27,873 | |||||||
| Restricted cash | 1,269 | 1,148 | 1,269 | 1,148 | |||||||||||
| Total cash, cash equivalents and restricted cash | $ | 19,647 | $ | 29,021 | $ | 19,647 | $ | 29,021 | |||||||
(1) Prior year amounts have been updated to conform to current period presentation.
Key Metrics and Non-GAAP Financial Information
| DISAGGREGATED REVENUE BY PRODUCT LINE (in thousands, unaudited) | |||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||
| Passenger segment | |||||||||||
| Short Distance | $ | 9,133 | $ | 10,703 | $ | 72,203 | $ | 70,700 | |||
| Jet and Other | 8,836 | 4,784 | 29,673 | 27,876 | |||||||
| Total | $ | 17,969 | $ | 15,487 | $ | 101,876 | $ | 98,576 | |||
| Medical segment | |||||||||||
| MediMobility Organ Transport | $ | 36,388 | $ | 31,991 | 146,817 | 126,604 | |||||
| Total | $ | 36,388 | $ | 31,991 | $ | 146,817 | $ | 126,604 | |||
| Total Revenue | $ | 54,357 | $ | 47,478 | $ | 248,693 | $ | 225,180 | |||
| IMPACT OF FORMER OPERATIONS IN CANADA ON REPORTED REVENUE (in thousands except percentages, unaudited) | ||||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||||||
| 2024 | 2023 | % Change | 2024 | 2023 | % Change | |||||||||||||||
| Revenue | $ | 54,357 | $ | 47,478 | 14.5 | % | $ | 248,693 | $ | 225,180 | 10.4 | % | ||||||||
| Canada revenue | — | (2,942 | ) | (6,384 | ) | (10,474 | ) | |||||||||||||
| Revenue excluding Canada | $ | 54,357 | $ | 44,536 | 22.1 | % | $ | 242,309 | $ | 214,706 | 12.9 | % | ||||||||
| Short Distance | $ | 9,133 | $ | 10,703 | (14.7 | )% | $ | 72,203 | $ | 70,700 | 2.1 | % | ||||||||
| Canada revenue | — | (2,942 | ) | (6,384 | ) | (10,474 | ) | |||||||||||||
| Short Distance Revenue excluding Canada | $ | 9,133 | $ | 7,761 | 17.7 | % | $ | 65,819 | $ | 60,226 | 9.3 | % | ||||||||
| SEGMENT INFORMATION: REVENUE, FLIGHT PROFIT, FLIGHT MARGIN, ADJUSTED EBITDA WITH RECONCILIATION TO TOTAL ADJUSTED EBITDA (in thousands except percentages, unaudited) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Passenger Revenue | $ | 17,969 | $ | 15,487 | $ | 101,876 | $ | 98,576 | |||||||
| Medical Revenue | 36,388 | 31,991 | 146,817 | 126,604 | |||||||||||
| Total Revenue | $ | 54,357 | $ | 47,478 | $ | 248,693 | $ | 225,180 | |||||||
| Passenger Flight Profit | $ | 4,123 | $ | 2,580 | $ | 25,878 | $ | 19,444 | |||||||
| Medical Flight Profit | 8,466 | 6,430 | 33,041 | 22,678 | |||||||||||
| Total Flight Profit | $ | 12,589 | $ | 9,010 | $ | 58,919 | $ | 42,122 | |||||||
| Passenger Flight Margin | 22.9 | % | 16.7 | % | 25.4 | % | 19.7 | % | |||||||
| Medical Flight Margin | 23.3 | % | 20.1 | % | 22.5 | % | 17.9 | % | |||||||
| Total Flight Margin | 23.2 | % | 19.0 | % | 23.7 | % | 18.7 | % | |||||||
| Passenger Adjusted EBITDA | $ | (156 | ) | $ | (2,635 | ) | $ | 3,568 | $ | (4,988 | ) | ||||
| Medical Adjusted EBITDA | 5,502 | 2,505 | 19,286 | 10,754 | |||||||||||
| Adjusted unallocated corporate expenses and software development | (5,733 | ) | (5,118 | ) | (21,649 | ) | (22,399 | ) | |||||||
| Total Adjusted EBITDA | $ | (387 | ) | $ | (5,248 | ) | $ | 1,205 | $ | (16,633 | ) | ||||
| LAST TWELVE MONTHS PASSENGER ADJUSTED EBITDA (in thousands, unaudited) | |||||||||||||||||
| Three Months Ended | |||||||||||||||||
| Last Twelve Months | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | |||||||||||||
| Passenger Adjusted EBITDA | $ | 3,568 | $ | (156 | ) | $ | 5,593 | $ | 782 | $ | (2,651 | ) | |||||
| SEATS FLOWN - ALL PASSENGER FLIGHTS (unaudited) | |||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||
| 2024 | 2023 | 2024 | 2023 | ||||
| Seats flown – all passenger flights(1) | 16,661 | 17,977 | 94,733 | 95,781 | |||
(1) We discontinued our operations in Canada on August 31, 2024. As a result, the Seats Flown metric above excludes activity in Canada for the years ended December 31, 2024, and 2023. The Seats Flown in Canada totaled nil and 15,251 for the three months ended December 31, 2024 and 2023, respectively and 36,465 and 55,924 for the years ended December 31, 2024 and 2023, respectively.
| REVENUE, FLIGHT PROFIT, FLIGHT MARGIN, ADJUSTED SG&A, ADJUSTED EBITDA (in thousands except percentages, unaudited) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenue | $ | 54,357 | $ | 47,478 | $ | 248,693 | $ | 225,180 | |||||||
| Flight Profit | 12,589 | 9,010 | 58,919 | 42,122 | |||||||||||
| Flight Margin | 23.2 | % | 19.0 | % | 23.7 | % | 18.7 | % | |||||||
| Adjusted SG&A | 13,618 | 14,338 | 59,388 | 58,989 | |||||||||||
| Adjusted SG&A as a percentage of revenue | 25.1 | % | 30.2 | % | 23.9 | % | 26.2 | % | |||||||
| Depreciation included in Flight Profit | 642 | 80 | 1,674 | 234 | |||||||||||
| Adjusted EBITDA | $ | (387 | ) | $ | (5,248 | ) | $ | 1,205 | $ | (16,633 | ) | ||||
| Adjusted EBITDA as a percentage of revenue | (0.7 | )% | (11.1 | )% | 0.5 | % | (7.4 | )% | |||||||
| RECONCILIATION OF REVENUE LESS COST OF REVENUE TO FLIGHT PROFIT AND GROSS PROFIT (in thousands except percentages, unaudited) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenue | $ | 54,357 | $ | 47,478 | $ | 248,693 | $ | 225,180 | |||||||
| Less: | |||||||||||||||
| Cost of revenue(1) | 41,768 | 38,468 | 189,774 | 183,058 | |||||||||||
| Depreciation and amortization(2) | 653 | 1,619 | 3,422 | 6,361 | |||||||||||
| Stock-based compensation | 36 | 69 | 185 | 193 | |||||||||||
| Other(3) | 2,874 | 3,217 | 14,660 | 13,110 | |||||||||||
| Gross Profit | $ | 9,026 | $ | 4,105 | $ | 40,652 | $ | 22,458 | |||||||
| Gross Margin | 16.6 | % | 8.6 | % | 16.3 | % | 10.0 | % | |||||||
| Gross Profit | $ | 9,026 | $ | 4,105 | $ | 40,652 | $ | 22,458 | |||||||
| Reconciling items: | |||||||||||||||
| Depreciation and amortization(2) | 653 | 1,619 | 3,422 | 6,361 | |||||||||||
| Stock-based compensation | 36 | 69 | 185 | 193 | |||||||||||
| Other(3) | 2,874 | 3,217 | 14,660 | 13,110 | |||||||||||
| Flight Profit | $ | 12,589 | $ | 9,010 | $ | 58,919 | $ | 42,122 | |||||||
| Flight Margin | 23.2 | % | 19.0 | % | 23.7 | % | 18.7 | % | |||||||
(1) Cost of revenue consists of flight costs paid to operators of aircraft and vehicles, landing fees, depreciation of aircraft and vehicles, operating lease cost, internal costs incurred in generating organ ground transportation revenue using the Company's owned vehicles and costs of operating our owned aircraft including fuel, management fees paid to the operator, maintenance costs and pilot salaries.
(2) Real estate depreciation and intangibles amortization included within general and administrative.
(3) Other costs include credit card processing fees, direct staff costs (primarily customer facing, logistics and coordination personnel), commercial costs and establishment costs.
| RECONCILIATION OF TOTAL OPERATING EXPENSES TO ADJUSTED SG&A (in thousands except percentages, unaudited) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenue | $ | 54,357 | $ | 47,478 | $ | 248,693 | $ | 225,180 | |||||||
| Total operating expenses | 62,729 | 83,111 | 282,619 | 293,297 | |||||||||||
| Subtract: | |||||||||||||||
| Cost of revenue | 41,768 | 38,468 | 189,774 | 183,058 | |||||||||||
| SG&A | $ | 20,961 | $ | 44,643 | $ | 92,845 | $ | 110,239 | |||||||
| SG&A as percentage of Revenue | 38.6 | % | 94.0 | % | 37.3 | % | 49.0 | % | |||||||
| Adjustments to reconcile SG&A to Adjusted SG&A | |||||||||||||||
| Subtract: | |||||||||||||||
| Depreciation and amortization included in SG&A | 888 | 1,726 | 4,288 | 6,877 | |||||||||||
| Stock-based compensation | 4,561 | 3,153 | 19,995 | 12,501 | |||||||||||
| Legal and regulatory advocacy fees(1) | 1,286 | 46 | 1,713 | 686 | |||||||||||
| Executive severance costs | — | 182 | 140 | 447 | |||||||||||
| SOX readiness costs | 97 | 72 | 399 | 252 | |||||||||||
| Contingent consideration compensation (earn-out)(2) | — | 4,373 | — | 9,734 | |||||||||||
| M&A transaction costs | 72 | — | 241 | — | |||||||||||
| Impairment of intangible assets | — | 20,753 | 5,759 | 20,753 | |||||||||||
| Gain on lease modification | (519 | ) | — | (519 | ) | — | |||||||||
| Restructuring costs(3) | 958 | — | 1,441 | — | |||||||||||
| Adjusted SG&A | $ | 13,618 | $ | 14,338 | $ | 59,388 | $ | 58,989 | |||||||
| Adjusted SG&A as percentage of Revenue | 25.1 | % | 30.2 | % | 23.9 | % | 26.2 | % | |||||||
(1) Includes legal advocacy fees that we do not consider representative of legal and regulatory advocacy costs that we will incur from time to time in the ordinary course of our business. For the three months and year ended December 31, 2024, these costs primarily related to the Drulias lawsuit and to the proposed restrictions at East Hampton Airport. For the three months and year ended December 31, 2023, these costs primarily relate to certain proposed restrictions at East Hampton Airport and potential operational restrictions on large jet aircraft at Westchester Airport.
(2) Represents contingent consideration in connection with the Trinity acquisition; 2023 was the last year subject to an earn-out payment.
(3) Includes severance, retention, legal and other one-time restructuring costs associated with a reorganization of Blade Europe and one-time termination fee of Blade Canada routes.
| RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA (in thousands except percentages, unaudited) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net loss | $ | (9,793 | ) | $ | (33,941 | ) | $ | (27,307 | ) | $ | (56,076 | ) | |||
| Depreciation and amortization | 1,530 | 1,806 | 5,962 | 7,111 | |||||||||||
| Stock-based compensation | 4,561 | 3,153 | 19,995 | 12,501 | |||||||||||
| Impairment of intangible assets | — | 20,753 | 5,759 | 20,753 | |||||||||||
| Change in fair value of warrant liabilities | 3,116 | 1,698 | 850 | (2,125 | ) | ||||||||||
| Realized gain from sales of short-term investments | — | (103 | ) | — | (8 | ) | |||||||||
| Interest income | (1,590 | ) | (2,264 | ) | (7,214 | ) | (8,442 | ) | |||||||
| Income tax benefit | (105 | ) | (1,023 | ) | (255 | ) | (1,466 | ) | |||||||
| Legal and regulatory advocacy fees(1) | 1,286 | 46 | 1,713 | 686 | |||||||||||
| Executive severance costs | — | 182 | 140 | 447 | |||||||||||
| SOX readiness costs | 97 | 72 | 399 | 252 | |||||||||||
| Contingent consideration compensation (earn-out)(2) | — | 4,373 | — | 9,734 | |||||||||||
| M&A transaction costs | 72 | — | 241 | — | |||||||||||
| Gain on lease modification | (519 | ) | — | (519 | ) | — | |||||||||
| Restructuring costs(3) | 958 | — | 1,441 | — | |||||||||||
| Adjusted EBITDA | $ | (387 | ) | $ | (5,248 | ) | $ | 1,205 | $ | (16,633 | ) | ||||
| Revenue | $ | 54,357 | $ | 47,478 | $ | 248,693 | $ | 225,180 | |||||||
| Adjusted EBITDA as a percentage of Revenue | (0.7 | )% | (11.1 | )% | 0.5 | % | (7.4 | )% | |||||||
(1) Includes legal advocacy fees that we do not consider representative of legal and regulatory advocacy costs that we will incur from time to time in the ordinary course of our business. For the three months and year ended December 31, 2024, these costs primarily related to the Drulias lawsuit and to the proposed restrictions at East Hampton Airport. For the three months and year ended December 31, 2023, these costs primarily relate to certain proposed restrictions at East Hampton Airport and potential operational restrictions on large jet aircraft at Westchester Airport.
(2) Represents contingent consideration in connection with the Trinity acquisition; 2023 was the last year subject to an earn-out payment.
(3) ) Includes severance, retention, legal and other one-time restructuring costs associated with a reorganization of Blade Europe and one-time termination fee of Blade Canada routes.
| RECONCILIATION OF NET CASH USED IN OPERATING ACTIVITIES TO FREE CASH FLOW AND FREE CASH FLOW BEFORE AIRCRAFT ACQUISITIONS (in thousands, unaudited) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net cash used in operating activities | $ | (1,752 | ) | $ | (9,320 | ) | $ | (2,519 | ) | $ | (32,349 | ) | |||
| Capitalized software development costs | (459 | ) | — | (2,119 | ) | — | |||||||||
| Purchase of property and equipment | (4,583 | ) | (24 | ) | (30,875 | ) | (2,109 | ) | |||||||
| Free Cash Flow | (6,794 | ) | (9,344 | ) | (35,513 | ) | (34,458 | ) | |||||||
| Aircraft Acquisition Capital Expenditures(1) | 3,242 | — | 25,165 | — | |||||||||||
| Free Cash Flow, before Aircraft Acquisitions | $ | (3,552 | ) | $ | (9,344 | ) | $ | (10,348 | ) | $ | (34,458 | ) | |||
(1) Represents capital expenditures for aircraft acquisitions, excluding capitalized maintenance subsequent to initial acquisition.
| LAST TWELVE MONTHS DISAGGREGATED REVENUE BY PRODUCT LINE (in thousands, unaudited) | |||||||||||||||
| Three Months Ended | |||||||||||||||
| Last Twelve Months | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | |||||||||||
| Product Line: | |||||||||||||||
| Short Distance | $ | 72,203 | $ | 9,133 | $ | 32,352 | $ | 20,908 | $ | 9,810 | |||||
| Jet and Other | 29,673 | 8,836 | 6,463 | 8,696 | 5,678 | ||||||||||
| MediMobility Organ Transport | 146,817 | 36,388 | 36,062 | 38,341 | 36,026 | ||||||||||
| Total Revenue | $ | 248,693 | $ | 54,357 | $ | 74,877 | $ | 67,945 | $ | 51,514 | |||||
About Blade Air Mobility
Blade Air Mobility provides air transportation and logistics for hospitals across the United States, where it is one of the largest transporters of human organs for transplant, and for passengers, with helicopter and fixed wing services primarily in the Northeast United States and Southern Europe. Based in New York City, Blade's asset-light model, coupled with its exclusive passenger terminal infrastructure and proprietary technologies, is designed to facilitate a seamless transition from helicopters and fixed-wing aircraft to Electric Vertical Aircraft (“EVA” or “eVTOL”), enabling lower cost air mobility that is both quiet and emission-free.
For more information, visit www.blade.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and may be identified by the use of words such as "will", “anticipate”, “believe”, “could”, “continue”, “expect", “estimate”, “may”, “plan”, “outlook”, “future”, "target", and “project” and other similar expressions and the negatives of those terms. These statements, which involve risks and uncertainties, relate to analyses and other information that are based on forecasts of future results and estimates of amounts not yet determinable and may also relate to Blade’s future prospects, developments and business strategies. In particular, such forward-looking statements include statements concerning Blade’s future financial and operating performance (including the discussion of financial and liquidity outlook and guidance for 2025 and beyond), the composition and performance of its fleet, results of operations, industry environment and growth opportunities and new product lines and partnerships. These statements are based on management’s current expectations and beliefs, as well as a number of assumptions concerning future events. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.
Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Blade’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements include: our continued incurrence of significant losses; failure of the markets for our offerings to grow as expected, or at all; our ability to effectively market and sell air transportation as a substitute for conventional methods of transportation; reliance on certain customers in our Passenger segment revenue; the inability or unavailability to use or take advantage of the shift, or lack thereof, to EVA technology; our ability to successfully enter new markets and launch new routes and services; any adverse publicity stemming from accidents involving small aircraft, helicopters or charter flights and, in particular, any accidents involving our third-party operators; any change to the ownership of our aircraft and the challenges related thereto; the effects of competition; harm to our reputation and brand; our ability to provide high-quality customer support; our ability to maintain a high daily aircraft usage rate; changes in consumer preferences, discretionary spending and other economic conditions; impact of natural disasters, outbreaks and pandemics, economic, social, weather, geopolitical, growth constraints, and regulatory conditions or other circumstances on metropolitan areas and airports where we have geographic concentration; the effects of climate change, including potential increased impacts of severe weather and regulatory activity; the availability of aircraft fuel; our ability to address system failures, defects, errors, or vulnerabilities in our website, applications, backend systems or other technology systems or those of third-party technology providers; interruptions or security breaches of our information technology systems; our placements within mobile applications; our ability to protect our intellectual property rights; our use of open source software; our ability to expand and maintain our infrastructure network; our ability to access additional funding; the increase of costs and risks associated with international expansion; our ability to identify, complete and successfully integrate future acquisitions; our ability to manage our growth; increases in insurance costs or reductions in insurance coverage; the loss of key members of our management team; our ability to maintain our company culture; our reliance on contractual relationships with certain transplant centers and Organ Procurement Organizations; effects of fluctuating financial results; our reliance on third-party operators; the availability of third-party operators; disruptions to third-party operators; increases in insurance costs or reductions in insurance coverage for our third-party aircraft operators; the possibility that our third-party aircraft operators may illegally, improperly or otherwise inappropriately operate our branded aircraft; our reliance on third-party web service providers; changes in our regulatory environment; risks and impact of any litigation we may be subject to; regulatory obstacles in local governments; the expansion of domestic and foreign privacy and security laws; the expansion of environmental regulations; our ability to remediate any material weaknesses or maintain internal controls over financial reporting; our ability to maintain effective internal controls and disclosure controls; changes in the fair value of our warrants; and other factors beyond our control. Additional factors can be found in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the U.S. Securities and Exchange Commission. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and Blade undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, changes in expectations, future events or otherwise.
Contacts
For Investor Relations
Mathew Schneider
investors@blade.com
For Media Relations
Lee Gold
press@blade.com
FAQ
What was Blade Air Mobility's (BLDE) revenue growth in Q4 2024?
How much did Blade's (BLDE) Medical segment Adjusted EBITDA improve in Q4 2024?
What is Blade Air Mobility's (BLDE) financial outlook for 2025?
How much cash does Blade Air Mobility (BLDE) have at the end of 2024?
